Clinical trials: HIV-DDI
HIV Infections
Safety and Effectiveness of an Anti-HIV Drug Combination With and Without Hydroxyurea in Patients With Early HIV Infection
The purpose of this study is to compare the safety and effectiveness of an anti-HIV drug combination with and without hydroxyurea in patients with early HIV infection.
- Trial name
- NCT00006339
- Testing
- Indinavir sulfate, Ritonavir, Hydroxyurea
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Phase I/II Double-Blind Controlled Trial to Determine the Safety and Immunogenicity of HIV-1 MN rgp160 Immuno AG Vaccine Therapy in HIV-Infected Individuals With Greater Than or Equal to 500/mm3 CD4+ T Cells and 200-400/mm3 CD4+ T Cells
To evaluate the safety and immunogenicity of HIV-1 MN rgp160 (Immuno-AG) in HIV-infected patients. To evaluate the immunogenicity of HIV-1 MN rgp160 immunogen by lymphocyte proliferation, specific antibody responses, and DTH…
- Trial name
- NCT00000822
- Testing
- Ritonavir, gp160 Vaccine (Immuno-AG), Stavudine
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
The Effectiveness of Two Anti-HIV Treatments in HIV-Infected Patients
To determine the effects of zidovudine (AZT) alone and in combination with didanosine (ddI) on viral load in the lymphoid tissue and blood of antiretroviral-naive, HIV-infected patients with CD4 counts greater than or equal to…
- Trial name
- NCT00001057
- Testing
- Zidovudine, Didanosine
- Where
- 7 sites in United States
- Volunteers
- 105 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Pilot Open Label Trial of HIV Therapy With d4T (Stavudine), ddI (Didanosine), Nelfinavir and Hydroxyurea in Subjects With Early Asymptomatic HIV Infection
To assess the magnitude and duration of the antiviral activity in plasma and the incidence and time to total suppression of detectable HIV RNA in plasma.
- Trial name
- NCT00002176
- Testing
- Hydroxyurea, Nelfinavir mesylate, Stavudine
- Where
- United States
- Sponsor
- Bristol-Myers Squibb
HIV Infections
Bioequivalence Study of Didanosine in Children Treated for HIV
The purpose of this study is to show that the administration of 400/mg/m2/day of didanosine(ddI) during the meal is bioequivalent to the administration of 240/mg/m2/day of didanosine during fasting, in HIV infected children…
- Trial name
- ddI (NCT00668356)
- Testing
- didanosine
- Where
- France
- Volunteers
- 26 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
HIV Infections
A Comparison of Two Anti-HIV Triple-Drug Combinations in HIV-Infected Patients
The purpose of this study is to compare the safety and effectiveness of two anti-HIV drug combinations when given to HIV-infected patients who have never been treated with anti-HIV drugs.
- Trial name
- NCT00002168
- Testing
- Indinavir sulfate, Lamivudine, Stavudine
- Where
- 13 sites in United States, Puerto Rico
- Volunteers
- 200 people
- Sponsor
- Bristol-Myers Squibb
HIV Infections
A Phase I Safety and Pharmacokinetics Study of 2',3'-Dideoxyinosine (ddI) Administered Twice Daily to Infants and Children With AIDS or Symptomatic HIV Infection
To determine the safety and maximum tolerated dose (MTD) of 2',3'-dideoxyinosine (ddI), given orally and intravenously, in infants and children with AIDS.
- Trial name
- NCT00000669
- Testing
- Didanosine
- Where
- 5 sites in United States
- Volunteers
- 25 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Randomized Comparative Trial of Zidovudine (AZT) Versus 2',3'-Dideoxyinosine (ddI) Versus AZT Plus ddI in Symptomatic HIV-Infected Children
To compare the effectiveness of treatment with zidovudine (AZT) compared to didanosine (ddI) and compared to the combination of AZT and ddI as determined by survival and disease progression.
- Trial name
- NCT00000637
- Testing
- Zidovudine, Didanosine
- Where
- 80 sites in United States, Puerto Rico
- Volunteers
- 819 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)